Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment-Reference-Cited by-同舟云学术

Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment

Published:2020-03 Issue:3 Volume:156 Page:561-567
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Havrilesky Laura J.^ORCID,Lim Stephanie,Ehrisman Jessie A.,Lorenzo Amelia,Alvarez Secord Angeles,Yang Jui-Chen,Johnson F. Reed,Gonzalez Juan Marcos,Reed Shelby D.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference40 articles.

1. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial

2. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

3. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N. Engl. J. Med.,2011

4. Final overall survival of a randomized trial of Bevacizumab for primary treatment of ovarian cancer;Tewari;J. Clin. Oncol.,2019

5. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J. Clin. Oncol.,2012

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021;Gynecologic Oncology;2024-11

2. The power of hope: Views of Ovarian Cancer patients on how maintenance therapy Affects their Lives (VOCAL);Future Oncology;2023-09-13

3. Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment;Patient Preference and Adherence;2023-09

4. One fixed dosing of a poly(adenosine diphosphate ribose) polymerase inhibitor does not fit all;Cancer;2023-04-14

5. Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance;Oncology and Therapy;2023-04-04